Vaccaro et al. present a systematic review and meta-analysis of the performance of human–AI combinations, finding that on average, human–AI combinations performed significantly worse than the ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

Total vaccine sales were down due to lower sales of Arexvy and Shingrix ... a series of filings and data readouts supporting future product momentum. So far this year, we've had 11 positive ...

Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix ... Phase III readouts and plans for five major new product approvals next year. GSK PLC (NYSE:GSK ...

Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix ... with 11 positive Phase III readouts and plans for five major new product approvals next year. GSK PLC ...

You can also include photos if you want. Once a doctor reviews your information, they’ll suggest a treatment plan for you. Products come as tablets, foams, and serums. Most product reviews are ...

Big pharma has long been a force for commercial broadcasters. Promotions for GSK’s respiratory vaccine Arexvy and its blockbuster shingles shot Shingrix are a big presence. But despite all the ...

GSK's vaccine sales, including RSV and Shingrix, decline amid changing US recommendations, impacting Q3 performance and ...

The U.K. firm, whose vaccines include Arexvy and Shingrix ... to offset lower vaccine sales and reflected successful new product launches in oncology and HIV, as well as the resilience we have ...

However, sales across critical divisions were lackluster, with key products such as the respiratory syncytial virus (RSV) vaccine, Arexvy, missing expectations by 21%, and Shingrix sales falling short ...